On July 6, WuXi Biologics rose 3.09% in regular trading, trading at HK$38.68/share, with turnover of HK$363 million.

On the news front, the company has maintained an intensive buyback pace, accumulating over 37.108 million shares repurchased since May 26, with total consideration of approximately HK$1.172 billion, signaling management confidence in the company's intrinsic value. Additionally, three factories at the company's Wuxi production base passed Brazil's ANVISA GMP certification with zero findings, further validating its global commercial manufacturing capabilities.

Within the Life Sciences Tools and Services sector, the overall sector exhibited broad strength. Among individual stocks, GenScript Biotech up 6.1%, WuXi XDC up 5.92%, XtalPi up 3.8%, WuXi AppTec up 2.11%, and Insilico up 1.66%, reflecting significant sector resonance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)